Associated Papers
Genetic and non-genetic drivers of histological progression and regression in MASLD.
Vilar-Gomez E et al.
Journal of Hepatology, 2026
Patatin-Like Phospholipase Domain Containing 3 I148M Variant Affects Hepatocellular Carcinoma Recurrence After Liver Resection.
Nakayama Y et al.
Liver International : Official Journal of the International Association for the Study of the Liver, 2026
Genetic Predisposition to MASLD: Potential for Therapeutic Management.
Karapanagiotidi F et al.
International Journal of Molecular Sciences, 2026
HLA DRB1*01 and *04 Predisposition to Rheumatoid Arthritis and Polymorphisms of the SLCO1B1, MTHFR and PNPLA3 Genes Are Not Associated with Fatty Liver and Hepatotoxicity.
Zekić T et al.
Journal of Clinical Medicine, 2026
Germline mutations and somatic mosaicism in steatotic liver diseases and related liver carcinogenesis.
Trépo E et al.
Nature Reviews. Gastroenterology & Hepatology, 2026
Influence of genetics on clinical trajectories in children with MASLD: role of the PNPLA3 I148M polymorphism.
Di Sessa A et al.
Journal of Endocrinological Investigation, 2026
Genetic variants underlying precancerous conditions of hepatocellular carcinoma.
Guerrero JJG et al.
International Journal of Cancer, 2026
A mitochondrial amidoxime-reducing component 1 (mARC1) A168T amino acid substitution does not confer protection from MASH and fibrosis in multiple mouse models of chronic liver disease.
Pandovski S et al.
The Biochemical Journal, 2026
Association between long-term exposure to PM10 and metabolic dysfunction-associated steatotic liver disease (MASLD) in subjects with disturbed metabolic homeostasis and genotypes at risk.
Di Ciaula A et al.
European Journal of Internal Medicine, 2026
Modeling Transmembrane 6 Superfamily Member 2 p.Glu167Lys-associated Steatotic Liver Disease Using Androgen-treated Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells.
Hirai A et al.
Gastro Hep Advances, 2026
Current and Emerging Issues in Familial Hypobetalipoproteinemia-related Steatotic Liver Diseases.
Lou TW et al.
Journal of Clinical and Translational Hepatology, 2025
Genetic risk of alcohol-related liver cirrhosis: Associations of PNPLA3, TM6SF2, and a two-variant polygenic risk score.
Nesic B et al.
Biomolecules & Biomedicine, 2025
PNPLA3-I148M genetic variant rewires lipid metabolism to drive programmed cell death in human hepatocytes.
Florentino RM et al.
Jci Insight, 2025
Newly identified single-nucleotide polymorphism associated with the transition from nonalcoholic fatty liver disease to liver fibrosis: results from a nested case-control study in the UK biobank.
Ling Y et al.
Annals of Medicine, 2025
Genetic predeterminants and recent advancements in steatotic liver disease: A roadmap toward precision hepatology.
Kumar G et al.
World Journal of Hepatology, 2025
[The role of the PNPLA3 gene rs738409 variant in the spectrum of metabolic dysfunction associated steatotic liver diseases].
Nádasdi Á et al.
Orvosi Hetilap, 2025
Modeling Familial MASH by iPSC-Hepatocytes.
Esteva-Font C et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
Unraveling the Role of BAG3 in Hepatic Fibrosis: Genetic and Biomarker Insights in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Motta BM et al.
International Journal of Molecular Sciences, 2025
Genomic Signatures of MASLD: How Genomics Is Redefining Our Understanding of Metabolic Liver Disease.
Saliba-Gustafsson P et al.
International Journal of Molecular Sciences, 2025
Artificial intelligence as a ploy to delve into the intricate link between genetics and mitochondria in patients with MASLD.
Longo M et al.
Jhep Reports : Innovation in Hepatology, 2025
Integrative functional genomics reveals transcriptional regulatory function of risk alleles for metabolic liver disease.
Hu W et al.
Research Square, 2025
Alpha-1 antitrypsin Pi*MZ variant increases the risk of liver disease progression in MASLD and MASH.
Jermy B et al.
Annals of Hepatology, 2025
Glucagon Receptor Deficiency Causes Early-Onset Hepatic Steatosis.
Cacciottolo TM et al.
Diabetes, 2025
Genome-wide interaction study with body mass index identifies CYP7A1 and GIPR as genetic modulators of metabolic dysfunction-associated steatotic liver disease.
Jamialahmadi O et al.
Clinical and Molecular Hepatology, 2025
Germline Variants Influence Chronic Liver Disease Progression through Distinct Pathways.
Vujkovic M et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
Loss of function of T-box 3 in the liver protects against MASLD.
Maher JJ
The Journal of Clinical Investigation, 2025
Human-induced pluripotent stem cell-based hepatic modeling of lipid metabolism-associated TM6SF2-E167K variant.
Faccioli LAP et al.
Hepatology (baltimore, Md.), 2025
Associations of Alcohol Consumption and Genetic Predisposition to Hepatic Steatosis With Liver-Related Events: Results From Large Population-Based Cohort Studies.
Xue H et al.
Gastroenterology, 2025
iPSC-Derived Hepatocytes from Patients with MASLD Exhibit Early Mitochondrial Dysfunction.
Le Guillou D et al.
Biorxiv : the Preprint Server for Biology, 2025
Contribution of PNPLA3, GCKR, MBOAT7, NCAN, and TM6SF2 Genetic Variants to Hepatocellular Carcinoma Development in Mexican Patients.
Arreola Cruz A et al.
International Journal of Molecular Sciences, 2025
Meta-Analysis: Effects of Steatotic Liver Disease-Associated Genetic Risk Alleles on Longitudinal Outcomes.
Kubina M et al.
Alimentary Pharmacology & Therapeutics, 2025
A novel human hepatocyte cell line to study PNPLA3-associated steatotic liver disease.
Huang G et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology, 2025
VLDL lipidomics reveals hepatocellular lipidome changes in metabolic dysfunction-associated steatotic liver disease.
Guardamino Ojeda D et al.
Hepatology Communications, 2025
Interplay of PNPLA3 and TM6SF2 variants in modulating the risk of hepatocellular carcinoma among Egyptian hepatitis C patients.
Moaz IM et al.
Clinical and Experimental Hepatology, 2025
A Defective Circulating Mitochondrial Bioenergetics Profile Reflects the Hepatic One and Outlines Genetic MASLD.
Paolini E et al.
Antioxidants (basel, Switzerland), 2025
Genomic approaches to explore susceptibility and pathogenesis of alcohol use disorder and alcohol-associated liver disease.
Norden-Krichmar TM et al.
Hepatology (baltimore, Md.), 2025
Alpha-1 antitrypsin deficiency-associated liver disease: From understudied disorder to the poster child of genetic medicine.
Fromme M et al.
Hepatology Communications, 2025
Role of metabolic dysfunction-associated steatotic liver disease and of its genetics on kidney function in childhood obesity.
Di Sessa A et al.
International Journal of Obesity (2005), 2025
Downregulation of the MARC1 p.A165 risk allele reduces hepatocyte lipid content by increasing beta-oxidation.
Ciociola E et al.
Clinical and Molecular Hepatology, 2025
Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction-associated steatohepatitis.
Sakuma I et al.
Biorxiv : the Preprint Server for Biology, 2025
PNPLA3 I148M Interacts With Environmental Triggers to Cause Human Disease.
Speliotes EK et al.
Liver International : Official Journal of the International Association for the Study of the Liver, 2025
Genetic Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease.
Pei Y et al.
Gut and Liver, 2025
Recent advances in MASLD genetics: Insights into disease mechanisms and the next frontiers in clinical application.
Chen VL et al.
Hepatology Communications, 2025